Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. (Q54480785)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

Mauro Giuseppe Mastropasqua

9 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Paolo Veronesi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Marco Colleoni

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

G Cancello

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

N Rotmensz

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

G Viale

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

G Pruneri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

E Montagna

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

M Iorfida

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

M Mazza

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Balduzzi

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Luini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

M Intra

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

A Goldhirsch

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

28 September 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

661-668

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

Repeated observation of breast tumor subtypes in independent gene expression data sets

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Molecular profiles of progesterone receptor loss in human breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS430

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS430

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json

release_nc3lx2cu5rbs5hsvh7yti3djci

9 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nc3lx2cu5rbs5hsvh7yti3djci

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23022996%20AND%20SRC:MED&resulttype=core&format=json